Insilico Medicine inaugurates R&D centre in Montréal
This laboratory will tap into the potential of artificial intelligence to enhance drug discovery. The centre will also serve as a central hub for the company’s North American operations.
Some fifteen experts are already on hand to increase the efficiency and accuracy of the drug discovery process by using a generative AI software.
The biotech company, which has offices in Hong Kong, New York and elsewhere in the world, is also unveiling its latest version of the Pharma.AI platform, with three main objectives:
- Target discovery
- Design drug-like novel molecules
- Clinical trial prediction and optimization
In an interview with La Presse, Petrina Kamya, President of Insilico Medicine Canada, explained that Montréal’s “world-class” university research programs in AI, its “thriving” ecosystem of start-ups and the public sector support led the company to choose the region for this new R&D centre.
Insilico Medicine’s founder and CEO, Alex Zhavoronkov, was also on hand to inaugurate the facility and announce that a drug developed by the company’s Pharma.AI platform had passed a groundbreaking milestone in its quest for approval.
Greater Montréal’s life sciences sector has been growing exponentially over the past five years. In 2022, nearly 20% of foreign direct investment projects supported by Montréal International came from this vital industry, compared with just 1% in 2017.
To learn more about Insilico Medicine’s activities and ambitions in Montréal, read the La Presse article. And to learn more about Greater Montréal’s assets, take a look at our life sciences and health technologies industry profile and contact our expert.